Skip to main content
. 2018 May 1;2(3):429–438. doi: 10.1002/rth2.12102

Figure 1.

Figure 1

(A) Risk of recurrent venous thromboembolism in 6 months in randomized controlled trials of LMWH vs VKA (random effect model). (B) Risk of major bleeding in 6 months in randomized controlled trials of LMWH vs VKA (random effect model). CI, confidence interval; LMWH, low‐molecular‐weight heparin; M‐H, Mantel‐Haenszel; VKA, vitamin K antagonists